



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Romosozumab

Cat. No.:	HY-P9982
CAS No.:	909395-70-6
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis ^{[1][2]} .								
In Vivo	<p>Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys^[1].</p> <p>Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass, architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Male cynomolgus monkeys^[1]</td></tr><tr><td>Dosage:</td><td>30 mg/kg</td></tr><tr><td>Administration:</td><td>Subcutaneous injection; 30 mg/kg twice a week for 10 weeks</td></tr><tr><td>Result:</td><td>Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.</td></tr></table>	Animal Model:	Male cynomolgus monkeys ^[1]	Dosage:	30 mg/kg	Administration:	Subcutaneous injection; 30 mg/kg twice a week for 10 weeks	Result:	Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
Animal Model:	Male cynomolgus monkeys ^[1]								
Dosage:	30 mg/kg								
Administration:	Subcutaneous injection; 30 mg/kg twice a week for 10 weeks								
Result:	Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.								

REFERENCES

[1]. Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. *Drugs Aging*. 2020 Nov;37(11):845-855.

[2]. Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. *J Bone Miner Res*. 2017 Apr;32(4):788-801.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA